Abstract
ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Current Bioactive Compounds
Title: AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Volume: 7 Issue: 1
Author(s): David P. Nowotnik
Affiliation:
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Abstract: ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Export Options
About this article
Cite this article as:
P. Nowotnik David, AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer, Current Bioactive Compounds 2011; 7 (1) . https://dx.doi.org/10.2174/157340711795163794
DOI https://dx.doi.org/10.2174/157340711795163794 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Mechanical Engineering Physical Activity and Cancer Prevention: Updating the Evidence. The Role of Oxidative Stress in Carcinogenesis
Current Cancer Therapy Reviews Opportunities of Finding Novel Anti-Infective Agents from Plant Cell Cultures
Current Medicinal Chemistry - Anti-Infective Agents Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Synthesis, Characterization and In Vitro Antiproliferative Effects of Novel 5-Amino Pyrazole Derivatives against Breast Cancer Cell Lines
Recent Patents on Anti-Cancer Drug Discovery The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry In Vitro, In Vivo and In Silico Analysis of the Anticancer and Estrogen-like Activity of Guava Leaf Extracts
Current Medicinal Chemistry Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3
Anti-Cancer Agents in Medicinal Chemistry Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Nano Traditional Chinese Medicine: Current Progresses and Future Challenges
Current Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design Dysregulation of Lysyl Oxidases Expression in Diabetic Nephropathy and Renal Cell Carcinoma
Current Drug Targets The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism